Osteopontin; as a target molecule for the treatment of inflammatory diseases

Current Drug Targets

Volumn 11, Issue 4, 2010, Pages 494-505

  Morimoto, Junko ^a   Kon, Shigeyuki ^a   Matsui, Yutaka ^a   Uede, Toshimitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Alpha4 integrin; Apha9 integrin; Autoimmune disease; Conventional DC; Intracellular form of Opn; Plasmacytoid DC; Secreted form of Opn; Thrombin cleaved form of Opn

Indexed keywords

ALPHA9 INTEGRIN ANTIBODY; ANTIBODY; BETA INTERFERON; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 23C3; NEUTRALIZING ANTIBODY; OSTEOPONTIN; OSTEOPONTIN ANTIBODY; SB 273005; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTIBODY;

ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CARDIOVASCULAR DISEASE; CROHN DISEASE; DRUG TARGETING; ENTERITIS; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; AUTOIMMUNE DISEASES; GENE THERAPY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OSTEOPONTIN; SIGNAL TRANSDUCTION;

EID: 77950833119     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790980321     Document Type: Review

References (132)

1. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-611
2. Cook AC, Chambers AF, Turley EA, Tuck AB. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 2006; 281: 24381-24389
3. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997; 121: 578-584 (Pubitemid 27259939)
4. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-161
5. Chakraborty G, Jain S, Patil TV, Kundu GC. Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 2008; 12: 2305-2318
6. Chellaiah MA, Hruska KA. The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int 2003; 72: 197-205
7. Chellaiah MA, Kizer N, Biswas R, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003; 14: 173-189 (Pubitemid 36106028)
8. Nakase T, Takaoka K, Hirakawa K, et al. Alterations in the expression of osteonectin, osteopontin and osteocalcin mRNAs during the development of skeletal tissues in vivo. Bone Miner 1994; 26: 109-122 (Pubitemid 2125037)
9. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 2002; 71: 145-154 (Pubitemid 36935480)
10. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem(Suppl 1998); 30-31: 92-102. (Pubitemid 29028730)
11. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-345
12. Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009; 11: 206-213
13. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-2309 (Pubitemid 350203943)
14. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008; 103: 4-13. (Pubitemid 351524472)
15. Maeno Y, Nakazawa S, Yamamoto N, et al. Osteopontin participates in Th1-mediated host resistance against nonlethal malaria parasite Plasmodium chabaudi chabaudi infection in mice. Infect Immun 2006; 74: 2423-2427
16. Nau GJ, Chupp GL, Emile JF, et al. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Pathol 2000; 157: 37-42. (Pubitemid 30641722)
17. Nau GJ, Liaw L, Chupp GL, Berman JS, Hogan BL, Young RA. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun 1999; 67: 4223-4230 (Pubitemid 29357049)
18. Oldberg A, Franzen A, Heinegard D, Pierschbacher M, Ruoslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 1988; 263: 19433-19436 (Pubitemid 19016420)
19. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83: 8819-8823 (Pubitemid 17223492)
20. Yokosaki Y, Tanaka K, Higashikawa F, Yamashita K, Eboshida A. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9-beta1 to osteopontin. Matrix Biol 2005; 24: 418-427 (Pubitemid 41765020)
21. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-512 (Pubitemid 26044470)
22. Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-226 (Pubitemid 29062981)
23. Patarca R, Freeman GJ, Singh RP, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145-161 (Pubitemid 19179701)
24. Pollack SB, Linnemeyer PA, Gill S. Induction of osteopontin mRNA expression during activation of murine NK cells. J Leukoc Biol 1994; 55: 398-400. (Pubitemid 24097248)
25. Chung JW, Kim MS, Piao ZH, et al. Osteopontin promotes the development of natural killer cells from hematopoietic stem cells. Stem Cells 2008; 26: 2114-2123
26. Gao C, Guo H, Wei J, Mi Z, Wai P, Kuo PC. S-nitrosylation of heterogeneous nuclear ribonucleoprotein A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages. J Biol Chem 2004; 279: 11236-11243 (Pubitemid 38401619)
27. Kawamura K, Iyonaga K, Ichiyasu H, Nagano J, Suga M, Sasaki Y. Differentiation, maturation, and survival of dendritic cells by osteopontin regulation. Clin Diagn Lab Immunol 2005; 12: 206-212
28. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864 (Pubitemid 30084330)
29. Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005; 106: 946-955 (Pubitemid 41076439)
30. Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH, Cantor H. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci USA 2005; 102: 17101-17106 (Pubitemid 41692690)
31. Gao C, Guo H, Mi Z, Wai PY, Kuo PC. Transcriptional regulatory functions of heterogeneous nuclear ribonucleoprotein-U and -A/B in endotoxin-mediated macrophage expression of osteopontin. J Immunol 2005; 175: 523-530 (Pubitemid 40884358)
32. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005; 106: 1232-1239 (Pubitemid 41129584)
33. Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005; 201: 1781-1791 (Pubitemid 41002897)
34. Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev Immunol 2009; 9: 137-141
35. Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006; 7: 498-506
36. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008; 29: 68-78.
37. Kitamura M, Iwabuchi K, Kitaichi N, et al. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol 2007; 178: 6567-6572 (Pubitemid 46717440)
38. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-1735
39. Heilmann K, Hoffmann U, Witte E, et al. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2008; 13: 1162-1174
40. Hikita ST, Vistica BP, Jones HR, et al. Osteopontin is proinflammatory in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2006; 47: 4435-4443 (Pubitemid 46579370)
41. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003; 53: 819-822 (Pubitemid 36622524)
42. Diao H, Kon S, Iwabuchi K, et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21: 539-550 (Pubitemid 39370509)
43. Kanayama M, Kurotaki D, Morimoto J, et al. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 2009; 182: 8015-8025
44. Barry ST, Ludbrook SB, Murrison E, Horgan CM. A regulated interaction between alpha5beta1 integrin and osteopontin. Biochem Biophys Res Commun 2000; 267: 764-769 (Pubitemid 30099398)
45. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995; 270: 26232-26238
46. Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713-724
47. Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res 2000; 258: 342-351
48. Green PM, Ludbrook SB, Miller DD, Horgan CM, Barry ST. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett 2001; 503: 75-79
49. Smith LL, Giachelli CM. Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res 1998; 242: 351-360
50. Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5.
51. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
52. Palmer EL, Ruegg C, Ferrando R, Pytela R, Sheppard D. Sequence and tissue distribution of the integrin alpha 9 subunit, a novel partner of beta 1 that is widely distributed in epithelia and muscle. J Cell Biol 1993; 123: 1289-1297 (Pubitemid 23352436)
53. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE. The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum 2007; 56: 1817-1826
54. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 2006; 113: 477-485
55. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23. (Pubitemid 36026342)
56. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925 (Pubitemid 41565956)
57. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28261-28267 (Pubitemid 37391532)
58. Yokosaki Y, Matsuura N, Sasaki T, et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999; 274: 36328-36334
59. Gao YA, Agnihotri R, Vary CP, Liaw L. Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. Matrix Biol 2004; 23: 457-466 (Pubitemid 39576660)
60. Ito K, Kon S, Nakayama Y, et al. The differential amino acid requirement within osteopontin in alpha4 and alpha9 integrinmediated cell binding and migration. Matrix Biol 2009; 28: 11-19
61. Kon S, Ikesue M, Kimura C, et al. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med 2008; 205: 25-33. (Pubitemid 351185712)
62. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173
63. Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-3719
64. Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008; 105: 9041-9046
65. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008; 29: 628-636
66. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009; 30: 108-119
67. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2: 762-764
68. Paty DW. The interferon-beta 1b clinical trial and its implications for other trials. Ann Neurol 1994; 36(Suppl): S113-4.
69. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37: 424-435
70. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472 (Pubitemid 29382036)
71. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-2043 (Pubitemid 38738218)
72. Steinman L. New targets for treatment of multiple sclerosis. J Neurol Sci 2008; 274: 1-4.
73. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin- deficient mice. J Immunol 2002; 168: 2096-2099 (Pubitemid 34171807)
74. Gold R, Hartung HP, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 1997; 20: 399-404 (Pubitemid 27364510)
75. Zettl UK, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol 1997; 178: 1-8. (Pubitemid 27250274)
76. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8: 74-83. (Pubitemid 46242361)
77. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
78. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-320 (Pubitemid 30060920)
79. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809
80. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-5055 (Pubitemid 29501273)
81. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-2204 (Pubitemid 29009378)
82. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-486
83. Petrow PK, Hummel KM, Schedel J, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000; 43: 1597-1605 (Pubitemid 30452481)
84. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002; 61(Suppl 2): ii96-9.
85. Yumoto K, Ishijima M, Rittling SR, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibodyinduced arthritis in mice. Proc Natl Acad Sci USA 2002; 99: 4556-4561 (Pubitemid 34286023)
86. Ihara H, Denhardt DT, Furuya K, et al. Parathyroid hormoneinduced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001; 276: 13065-13071 (Pubitemid 37385233)
87. Ohshima S, Kobayashi H, Yamaguchi N, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 2002; 46: 1094-1101 (Pubitemid 34303824)
88. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999; 103: 47-54. (Pubitemid 29031162)
89. Badger AM, Blake S, Kapadia R, et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum 2001; 44: 128-137 (Pubitemid 32113127)
90. Yamamoto N, Sakai F, Kon S, et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003; 112: 181-188 (Pubitemid 38056354)
91. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20: 133-147 (Pubitemid 28502453)
92. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001; 167: 1601-1608
93. Yamamoto N, Nakashima T, Torikai M, et al. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 2007; 7: 1460-1470 (Pubitemid 47302883)
94. Fan K, Dai J, Wang H, et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 2008; 58: 2041-2052 (Pubitemid 351988096)
95. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-1270 (Pubitemid 126449643)
96. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290
97. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608 (Pubitemid 34533555)
98. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035
99. Sato T, Nakai T, Tamura N, et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005; 54: 1254-1262 (Pubitemid 41192483)
100. McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999; 53: 255-263
101. Louis H, Le Moine O, Peny MO, et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 1997; 25: 1382-1389 (Pubitemid 27250758)
102. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000; 97: 5498-5503 (Pubitemid 30313747)
103. Tanaka K, Morimoto J, Kon S, et al. Effect of osteopontin alleles on beta-glucan-induced granuloma formation in the mouse liver. Am J Pathol 2004;164: 567-575 (Pubitemid 38364672)
104. Morimoto J, Inobe M, Kimura C, et al. Osteopontin affects the persistence of beta-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanisms. Int Immunol 2004; 16: 477-488 (Pubitemid 38313156)
105. Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003; 100: 7797-7802 (Pubitemid 36760049)
106. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351 (Pubitemid 36362792)
107. Saito Y, Kon S, Fujiwara Y, et al. Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther 2007; 18: 1205-1214 (Pubitemid 350261964)
108. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009; 71: 489-507
109. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825-857
110. Hammad H, Lambrecht BN, Pochard P, et al. Monocyte-derived dendritic cells induce a house dust mite-specific Th2 allergic inflammation in the lung of humanized SCID mice: involvement of CCR7. J Immunol 2002; 169: 1524-1534 (Pubitemid 34809199)
111. Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000; 106: 551-559 (Pubitemid 30666388)
112. de Heer HJ, Hammad H, Soullie T, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200: 89-98. (Pubitemid 38924731)
113. Xanthou G, Alissafi T, Semitekolou M, et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 2007; 13: 570-578 (Pubitemid 46828486)
114. Shinohara ML, Cantor H. The bridge between dendritic cells and asthma. Nat Med 2007;13: 536-538
115. Weiss JM, Renkl AC, Maier CS, et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001; 194: 1219-1229
116. Hansson G.K. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7(Suppl 1): 328-331
117. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804
118. Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993; 143: 1003-1008 (Pubitemid 24070540)
119. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393-2402
120. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-1696 (Pubitemid 23304531)
121. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; 92: 2814-2820 (Pubitemid 24006549)
122. O'Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994; 14: 1648-1656 (Pubitemid 24312226)
123. Chiba S, Okamoto H, Kon S, et al. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 2002; 16: 111-117 (Pubitemid 34464396)
124. Matsui Y, Rittling SR, Okamoto H, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1029-1034 (Pubitemid 36713556)
125. Isoda K, Nishikawa K, Kamezawa Y, et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002; 91: 77-82. (Pubitemid 34778945)
126. Strom A, Franzen A, Wangnerud C, Knutsson AK, Heinegard D, Hultgardh-Nilsson A. Altered vascular remodeling in osteopontindeficient atherosclerotic mice. J Vasc Res 2004; 41: 314-322 (Pubitemid 39370274)
127. Bruemmer D, Collins AR, Noh G, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003; 112: 1318-1331 (Pubitemid 38057686)
128. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 1997; 17: 188-193
129. Speer MY, Chien YC, Quan M, et al. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 2005; 66: 324-333 (Pubitemid 40471047)
130. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178 (Pubitemid 29070112)
131. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; 275: 20197-20203 (Pubitemid 30441631)
132. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196: 1047-1055